L. Crinò

Everolimus is an active agent in medullary thyroid cancer: a clinical and <i>in vitro</i> study

Antongiulio Faggiano, Valeria Ramundo, Alessandra Dicitore et al. · Journal of Cellular and Molecular Medicine · 2011 · 45 citations · Full text

Medicine, Oncology, Pharmacology +17

Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.

L. Crinò, Anna Maria Mosconi, Giorgio V. Scagliotti et al. · PubMed · 1998 · 22 citations

Medicine, Oncology, Pharmacotherapy +9

O-271 Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer

Giorgio V. Scagliotti, C. Kortsik, C. Manegold et al. · Lung Cancer · 2003 · 21 citations

Medicine, Oncology, Pharmacology +13

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

Fabrice Barlési, Martin Steins, Leora Horn et al. · Annals of Oncology · 2016 · 21 citations

Pharmacy, Pharmacotherapy, Outcomes Research +6

141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

Enriqueta Felip, L. Crinò, D.-W. Kim et al. · Journal of Thoracic Oncology · 2016 · 19 citations · Full text

Medicine, Oncology, Pharmacology +16